Macrolides are a class of antibiotics defined by a large macrocyclic lactone ring attached to one or more deoxy sugars. They inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking translocation of the growing peptide chain. The class encompasses erythromycin (the prototype), the semisynthetic second-generation agents clarithromycin and azithromycin, and the ketolide telithromycin. Their activity against intracellular and atypical pathogens — organisms that do not respond to beta-lactams — gives macrolides an indispensable role in respiratory and sexually transmitted infection management.1
Mechanism of action. Macrolides bind reversibly to the 23S ribosomal ribonucleic acid (rRNA) component of the 50S ribosomal subunit at a site in the peptide exit tunnel, immediately adjacent to the peptidyl transferase center. This binding sterically obstructs the passage of the elongating nascent peptide through the ribosomal exit tunnel, causing premature dissociation of the peptidyl-transfer ribonucleic acid (tRNA) from the ribosome and halting chain elongation. The binding is reversible, making the effect bacteriostatic rather than bactericidal in most contexts. At very high concentrations or against particularly susceptible organisms, macrolides can produce bactericidal effects, but bacteriostatic activity is the clinically relevant mode. Unlike tetracyclines, which block aminoacyl-tRNA entry at the A site, macrolides act downstream at the point of peptide chain exit, providing a distinct mechanism that is not cross-resistant with tetracyclines or aminoglycosides by default.12
Ketolides. Telithromycin is a ketolide, a structural modification of erythromycin in which the cladinose sugar at position C-3 is replaced by a keto group and a carbamate extension at C-11/C-12. This modification allows telithromycin to bind the 23S rRNA at two sites rather than one — the standard macrolide site plus an additional site on domain II — conferring activity against macrolide-resistant organisms that carry the erm methylase gene. Telithromycin has largely been withdrawn from routine clinical use in many countries following reports of severe hepatotoxicity and exacerbation of myasthenia gravis (MG), but understanding its structural basis remains instructive for understanding macrolide resistance.8
Antimicrobial spectrum. Macrolides are active against a broad range of Gram-positive organisms, including Streptococcus pyogenes, Streptococcus pneumoniae (where resistance has become prevalent), and Staphylococcus aureus (susceptible strains only). They are the agents of choice or preferred alternatives against atypical intracellular pathogens including Mycoplasma pneumoniae, Chlamydophila pneumoniae (formerly Chlamydia pneumoniae), Legionella pneumophila, Chlamydia trachomatis, and Ureaplasma urealyticum. Among Gram-negative organisms, macrolides have meaningful activity against Haemophilus influenzae (azithromycin and clarithromycin more than erythromycin, which has limited intrinsic activity), Moraxella catarrhalis, Bordetella pertussis (whooping cough), Helicobacter pylori (in combination regimens), Campylobacter jejuni (azithromycin), and Mycobacterium avium complex (MAC). Macrolides do not have reliable activity against enteric Gram-negative rods, Pseudomonas aeruginosa, or anaerobes.13
Anti-inflammatory properties. Macrolides possess anti-inflammatory and immunomodulatory effects that are independent of their antimicrobial activity and contribute to their clinical utility in chronic respiratory conditions. Long-term low-dose azithromycin reduces exacerbation frequency in chronic obstructive pulmonary disease (COPD) and in non-cystic fibrosis bronchiectasis, effects attributed to suppression of neutrophil recruitment, inhibition of interleukin-8 and interleukin-6 production, reduction of mucus hypersecretion, and impairment of biofilm formation by colonizing pathogens. These immunomodulatory properties are also responsible for the benefit of macrolides in diffuse panbronchiolitis, a disease prevalent in East Asia, where long-term low-dose erythromycin has been the standard of care.3
Spectrum comparison across agents. Erythromycin, the original macrolide, has narrow Gram-negative coverage and is the most susceptible to acid degradation in the stomach, limiting oral bioavailability. Clarithromycin improves on erythromycin by achieving better H. influenzae coverage (partly through its active metabolite 14-hydroxyclarithromycin) and superior acid stability. Azithromycin has a distinctly expanded Gram-negative spectrum compared to erythromycin, including better activity against H. influenzae, Campylobacter, Neisseria gonorrhoeae, and Mycobacterium avium complex (MAC). Azithromycin also differs pharmacokinetically by achieving extremely high intracellular tissue concentrations, a characteristic that shapes both its efficacy and its resistance selection profile. Among the three major macrolides, azithromycin has the broadest Gram-negative coverage and the least propensity for cytochrome P450 3A4 (CYP3A4) drug interactions, while erythromycin is the most potent CYP3A4 inhibitor and carries the highest gastrointestinal (GI) burden.3
These three agents differ enough in spectrum, pharmacokinetics, tolerability, and drug interaction potential that they cannot be used interchangeably. Erythromycin: prototype, poor GI tolerability, highest CYP3A4 inhibition, narrowest Gram-negative spectrum. Clarithromycin: improved stability and tolerability, active metabolite adds H. influenzae coverage, significant CYP3A4 inhibitor. Azithromycin: broadest Gram-negative spectrum, unique pharmacokinetics with tissue accumulation and prolonged tissue half-life, minimal CYP3A4 inhibition. Selecting the right agent requires matching these properties to the clinical indication and the patient's concurrent medications.
The pharmacokinetic profiles of the three major macrolides diverge substantially, and these differences directly drive agent selection in clinical practice. Azithromycin's tissue pharmacokinetics are unique among antibiotics in their degree of cellular accumulation, while erythromycin and clarithromycin's cytochrome P450 3A4 (CYP3A4) inhibition creates clinically significant drug interactions that constrain their use in polypharmacy patients.56
Erythromycin pharmacokinetics. Erythromycin is a weak base that is acid-labile, undergoing significant degradation in the acidic gastric environment. Enteric-coated and ester formulations (erythromycin stearate, ethylsuccinate) were developed to improve oral delivery by delaying dissolution until the agent reaches the less acidic small intestine, but oral bioavailability remains variable and averages approximately 35 to 65% depending on the formulation and fed state. Erythromycin has a half-life of approximately 1.5 to 2 hours, requiring four-times-daily oral dosing for most indications. It distributes widely into tissues but achieves relatively modest intracellular concentrations compared to azithromycin. Erythromycin is metabolized extensively by and is a potent inhibitor of cytochrome P450 3A4 (CYP3A4), the enzyme responsible for metabolizing a large proportion of clinically used drugs. This bidirectional relationship with CYP3A4 means that erythromycin both uses and inhibits the enzyme simultaneously, leading to drug accumulation and toxicity when co-administered with CYP3A4 substrates.46
Clarithromycin pharmacokinetics. Clarithromycin is an acid-stable 6-O-methyl derivative of erythromycin, achieving oral bioavailability of approximately 50 to 55% with less dependence on formulation than erythromycin. Its half-life of approximately 3 to 7 hours supports twice-daily dosing. Clarithromycin is metabolized hepatically to its active 14-hydroxyclarithromycin metabolite, which is active against H. influenzae and contributes to the overall efficacy of clarithromycin in respiratory infections. Clarithromycin is a significant CYP3A4 inhibitor — intermediate in potency between erythromycin (strongest inhibitor) and azithromycin (negligible inhibitor) — and this interaction is clinically meaningful with statins, calcium channel blockers, warfarin, colchicine, and calcineurin inhibitors. Clarithromycin is also used in combination regimens for Helicobacter pylori eradication and for Mycobacterium avium complex (MAC) treatment and prophylaxis, where its tissue penetration and metabolite activity contribute to efficacy.4
Azithromycin pharmacokinetics. Azithromycin is an azalide — a 15-membered ring macrolide in which a nitrogen atom is incorporated into the lactone ring — a modification that profoundly alters its pharmacokinetic behavior. Oral bioavailability averages approximately 37% after oral dosing, reflecting extensive first-pass tissue uptake rather than poor gastrointestinal (GI) absorption; the drug is taken up avidly by cells as it crosses the gut wall and distributes into tissues before entering systemic circulation. Azithromycin achieves intracellular tissue concentrations 10 to 100 times higher than concurrent serum levels, concentrated in alveolar macrophages, polymorphonuclear neutrophils, monocytes, and fibroblasts. This tissue accumulation produces a tissue half-life of approximately 68 hours, supporting once-daily dosing and enabling short-course regimens (such as the 5-day Z-pack for respiratory infections or single-dose therapy for Chlamydia trachomatis urethritis and cervicitis). Serum concentrations, however, are substantially lower than tissue concentrations, making azithromycin unreliable for treating bacteremia.5
CYP3A4 inhibition hierarchy. Understanding the relative CYP3A4 inhibitory potency of macrolides is essential for safe prescribing in patients on multiple medications. Erythromycin is the most potent macrolide CYP3A4 inhibitor; it acts as a mechanism-based inhibitor by forming a stable inactive complex with the ferrous (Fe²⁺) form of CYP3A4 after being metabolized to a nitrosoalkane metabolite. This mechanism-based inhibition is irreversible and requires synthesis of new CYP3A4 enzyme for recovery. Clarithromycin operates by a similar mechanism and is a potent CYP3A4 inhibitor, though somewhat less potent than erythromycin in most assessments. Azithromycin, because it is not demethylated by CYP3A4 to the same extent, produces negligible CYP3A4 inhibition at clinical doses and is the preferred macrolide in patients on CYP3A4-sensitive medications. The clinical consequence of erythromycin and clarithromycin CYP3A4 inhibition includes elevated statin concentrations (particularly simvastatin and lovastatin, which have narrow therapeutic windows for myopathy), elevated colchicine levels causing potentially fatal toxicity, increased warfarin anticoagulation, and elevated calcineurin inhibitor concentrations (cyclosporine, tacrolimus) in transplant recipients.67
Elimination. All three macrolides undergo hepatic metabolism as the primary elimination route. Erythromycin and clarithromycin are eliminated via hepatic CYP3A4 metabolism and biliary excretion; dose reduction is required in severe hepatic impairment. Azithromycin is excreted primarily unchanged in bile, with minimal renal elimination; no dose adjustment is needed for renal impairment. Macrolide use in patients with hepatic impairment requires caution for all agents given their extensive hepatic metabolism and the risk of drug accumulation and QT (cardiac repolarization interval) prolongation.6
When a macrolide is clinically indicated in a patient taking simvastatin, lovastatin, colchicine, warfarin, cyclosporine, tacrolimus, or other narrow-therapeutic-index CYP3A4 substrates, azithromycin is the macrolide of choice. Erythromycin and clarithromycin carry a real risk of precipitating statin-induced rhabdomyolysis, colchicine toxicity (potentially fatal in renal impairment), or supratherapeutic immunosuppressant levels in transplant patients. The drug interaction risk is not hypothetical — it is a leading cause of avoidable serious adverse events associated with this drug class.
Macrolide adverse effects span predictable gastrointestinal (GI) intolerance that limits adherence, serious cardiac rhythm disturbances from QT (cardiac repolarization interval) prolongation, and a range of drug interactions mediated through cytochrome P450 3A4 (CYP3A4) inhibition that can cause severe toxicity in patients on concurrent medications. The adverse effect profile differs meaningfully across the three major agents, with erythromycin carrying the highest burden across most categories.8
Gastrointestinal motility effects. GI intolerance is the most common reason for macrolide discontinuation and is most prominent with erythromycin. The mechanism is primarily pharmacological rather than direct mucosal toxicity: macrolides, particularly erythromycin, are potent agonists of motilin receptors in the GI tract. Motilin is an enteric hormone that stimulates gastric and small bowel smooth muscle contraction during the migrating motor complex of the interdigestive phase. Macrolide activation of motilin receptors accelerates gastric emptying and increases intestinal peristalsis, producing nausea, vomiting, abdominal cramping, and diarrhea. This prokinetic effect of erythromycin has been deliberately exploited therapeutically at sub-antimicrobial doses for gastroparesis, where it accelerates delayed gastric emptying. Clarithromycin causes similar but less severe GI effects than erythromycin. Azithromycin has the best GI tolerability of the three, producing motilin-mediated GI effects at a substantially lower incidence. GI intolerance is dose-dependent and can be reduced by taking macrolides with food (with the exception of azithromycin immediate-release tablets, which should be taken on an empty stomach for optimal absorption).8
QTc prolongation and cardiac arrhythmia. Macrolides prolong the cardiac QT interval by blocking the rapid component of the delayed rectifier potassium current (IKr), encoded by the human ether-a-go-go-related gene (hERG). Inhibition of IKr delays ventricular repolarization, prolonging the QT interval and increasing the risk of early afterdepolarizations that can trigger torsades de pointes (TdP), a potentially fatal polymorphic ventricular tachycardia. Among the three major macrolides, azithromycin and erythromycin carry the greatest QT-prolonging potential; clarithromycin is also associated with QT prolongation. A widely publicized cohort study by Ray et al. published in the New England Journal of Medicine in 2012 demonstrated a significantly increased rate of cardiovascular death in patients receiving azithromycin compared to amoxicillin or no antibiotic, concentrated primarily in patients with pre-existing cardiovascular disease. The risk of macrolide-associated TdP is highest in patients with pre-existing QT prolongation, hypokalemia, hypomagnesemia, bradycardia, advanced age, female sex, or concurrent use of other QT-prolonging agents.910
Hepatotoxicity. Erythromycin is associated with cholestatic hepatitis, a hypersensitivity reaction that occurs most commonly with the estolate ester formulation and presents with fever, right upper quadrant pain, elevated alkaline phosphatase and bilirubin, and eosinophilia, typically appearing 10 to 20 days after starting therapy and resolving after drug discontinuation. The reaction is more common in adults than children. The estolate formulation has been largely withdrawn from clinical practice in many countries for this reason. Clarithromycin and azithromycin can also cause hepatotoxicity but at a lower frequency than erythromycin estolate; the pattern tends toward mixed or hepatocellular injury rather than pure cholestasis. Telithromycin, the ketolide, was associated with severe and sometimes fatal acute liver failure, which was the primary driver of its withdrawal from routine use.8
Ototoxicity. High-dose macrolide therapy, particularly intravenous erythromycin at doses greater than 4 grams per day, has been associated with reversible sensorineural hearing loss, tinnitus, and vestibular disturbance. The mechanism is incompletely understood but likely involves effects on cochlear ion channels or hair cell function. The ototoxicity is dose-dependent and typically reversible within days to weeks of drug discontinuation, distinguishing it from aminoglycoside-associated ototoxicity, which is frequently permanent. Azithromycin ototoxicity has been reported predominantly in patients receiving high cumulative doses for Mycobacterium avium complex (MAC) prophylaxis or treatment. Clinicians should monitor for hearing changes in patients receiving prolonged macrolide courses, particularly at high doses or in combination with other ototoxic agents.8
CYP3A4-mediated drug interactions. The clinical consequences of erythromycin and clarithromycin CYP3A4 inhibition extend across multiple drug classes. Statins metabolized by CYP3A4 — primarily simvastatin, lovastatin, and to a lesser extent atorvastatin — accumulate to myotoxic levels, increasing the risk of myopathy and rhabdomyolysis; rosuvastatin and pravastatin, which are not CYP3A4 substrates, are preferred alternatives during macrolide therapy. Colchicine toxicity is a particularly serious interaction: in patients with renal impairment taking colchicine for gout who receive clarithromycin or erythromycin, colchicine levels can reach lethal concentrations because both CYP3A4 and the P-glycoprotein (P-gp) efflux pump that normally limits colchicine absorption are inhibited simultaneously. Warfarin anticoagulation is potentiated by macrolides through cytochrome P450 2C9 (CYP2C9) inhibition (also relevant for clarithromycin) and possible reduction of gut flora that produce vitamin K. In transplant recipients, clarithromycin and erythromycin substantially elevate cyclosporine and tacrolimus levels, requiring dose reduction and close monitoring to prevent nephrotoxicity and other calcineurin inhibitor toxicities.7
Concurrent administration of colchicine with a potent CYP3A4 and P-gp inhibitor such as clarithromycin or erythromycin can produce life-threatening colchicine toxicity, particularly in patients with any degree of renal impairment, where colchicine clearance is already reduced. Manifestations include severe GI toxicity, bone marrow suppression, multi-organ failure, and death. This combination is contraindicated in patients with renal or hepatic impairment. If a macrolide is needed for a patient on colchicine, azithromycin is the agent of choice.
Macrolides occupy a central role in the management of community-acquired respiratory infections, sexually transmitted infections, atypical pneumonia, and mycobacterial disease. Resistance has, however, eroded the reliability of macrolides for common pathogens including Streptococcus pneumoniae, Mycoplasma pneumoniae, and Neisseria gonorrhoeae in many geographic regions, requiring clinicians to integrate local resistance data into empiric prescribing decisions.11
Community-acquired pneumonia. Macrolides are first-line agents for outpatient community-acquired pneumonia (CAP) in previously healthy adults without recent antibiotic use or risk factors for drug-resistant Streptococcus pneumoniae (DRSP). Their activity against both typical respiratory pathogens (S. pneumoniae, H. influenzae for azithromycin and clarithromycin) and atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila) makes them uniquely suited for empiric monotherapy in this setting. Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) guidelines endorse macrolide monotherapy for outpatient CAP in low-risk patients in regions where macrolide resistance among pneumococcal isolates remains below 25%. In regions with higher resistance rates, a respiratory fluoroquinolone is preferred. For hospitalized CAP patients, a macrolide is combined with a beta-lactam to provide dual coverage of typical and atypical organisms.11
Sexually transmitted infections. Azithromycin 1 gram as a single oral dose was the standard treatment for uncomplicated urogenital Chlamydia trachomatis infection for decades, exploiting the drug's unique pharmacokinetics to achieve sustained intracellular concentrations from a single dose. However, emerging evidence of treatment failures and documented rising minimum inhibitory concentrations (MICs) for Mycoplasma genitalium, as well as concerns about resistance selection, have led updated Centers for Disease Control and Prevention (CDC) guidelines to prefer doxycycline 100 mg twice daily for 7 days over single-dose azithromycin for uncomplicated chlamydia in non-pregnant patients. Azithromycin remains the preferred agent for chlamydia in pregnancy, where tetracyclines are contraindicated. For Mycoplasma genitalium infections, azithromycin has historically been used but resistance is increasing significantly; moxifloxacin is now preferred for confirmed macrolide-resistant M. genitalium. Macrolides are no longer recommended as primary therapy for Neisseria gonorrhoeae due to widespread resistance.12
Pertussis and other specific indications. Azithromycin is the preferred agent for treatment and post-exposure prophylaxis of pertussis (Bordetella pertussis), having displaced erythromycin as the agent of choice due to its superior tolerability and shorter course. The standard regimen is azithromycin 500 mg on day 1 followed by 250 mg on days 2 through 5. Clarithromycin is an alternative. Macrolides are used for diphtheria carrier eradication (Corynebacterium diphtheriae) in combination with antitoxin. Azithromycin is used for Campylobacter jejuni gastroenteritis when antibiotic treatment is indicated (severe disease, immunocompromise), though fluoroquinolone resistance in Campylobacter has made azithromycin increasingly important in this role. Clarithromycin-based triple therapy (proton pump inhibitor, clarithromycin, amoxicillin or metronidazole) remains a standard regimen for H. pylori eradication, though clarithromycin resistance rates exceeding 15 to 20% in many regions have prompted bismuth quadruple therapy as an alternative.12
Mycobacterium avium complex. Clarithromycin and azithromycin are the cornerstone agents for Mycobacterium avium complex (MAC) treatment and prophylaxis. For MAC prophylaxis in human immunodeficiency virus (HIV)-infected patients with CD4 (cluster of differentiation 4) T-cell counts below 50 cells per microliter, azithromycin 1200 mg once weekly is the preferred regimen, effective in preventing disseminated MAC in severely immunocompromised patients. For active MAC treatment, clarithromycin 500 mg twice daily combined with ethambutol (with or without rifabutin) is the recommended regimen; azithromycin is used as an alternative to clarithromycin in patients who cannot tolerate it or have significant drug interactions with clarithromycin. Macrolide monotherapy for MAC is contraindicated because it rapidly selects for macrolide resistance through point mutations in the 23S rRNA gene at positions 2058 and 2059, rendering the organisms resistant to the entire class.13
Macrolide-lincosamide-streptogramin B (MLSB) resistance — erm methylase. The predominant macrolide resistance mechanism in Gram-positive bacteria is the MLSB resistance phenotype, encoded by erm (erythromycin ribosome methylation) genes. The erm methylase enzyme methylates the adenine residue at position 2058 (A2058) in the 23S rRNA of the 50S subunit, the primary macrolide binding site. This modification reduces the affinity of macrolides, lincosamides (clindamycin), and streptogramin B antibiotics for their shared binding region on the ribosome, conferring resistance to all three drug classes simultaneously. MLSB resistance can be constitutive (always expressed) or inducible (expressed only when the organism is exposed to a macrolide inducer). Inducible MLSB resistance is clinically important because organisms that test susceptible to clindamycin but resistant to erythromycin by disk diffusion may harbor inducible resistance; the double-disk diffusion D-zone test is used to detect this phenotype. Erm genes are widely disseminated on plasmids and transposons among streptococci, staphylococci, and enterococci.1415
M phenotype — mef efflux. The M (macrolide-only) resistance phenotype is conferred by the mef (macrolide efflux) gene, which encodes a proton-dependent efflux pump that transports macrolides out of the bacterial cell. Unlike MLSB resistance, mef-mediated efflux is specific to macrolides and does not confer resistance to lincosamides or streptogramin B, because clindamycin and quinupristin are not substrates for the mef pump. The M phenotype is particularly prevalent in S. pneumoniae in North America and produces low-level macrolide resistance (minimum inhibitory concentration (MIC) typically 1 to 32 mcg/mL, compared to MICs exceeding 64 mcg/mL for erm-mediated resistance). Organisms with the M phenotype may retain in vivo susceptibility to high-dose macrolide therapy in some anatomical sites, though clinical outcomes data for pneumococcal pneumonia caused by mef-carrying isolates are mixed. Both erm and mef resistance determinants are common in community S. pneumoniae isolates, with the relative prevalence of each mechanism varying geographically and over time.1415
Macrolide-resistant Mycoplasma pneumoniae. Macrolide-resistant Mycoplasma pneumoniae has emerged as a significant clinical problem, particularly in Asia, where resistance rates in some series exceed 90% of community-acquired M. pneumoniae isolates. Resistance is conferred by point mutations in the 23S rRNA gene at positions 2063 and 2064 (equivalent to positions 2058 and 2059 in Escherichia coli numbering), the same binding site targeted by erm methylase but disrupted here by structural change rather than methylation. Clinical manifestations in children with macrolide-resistant M. pneumoniae pneumonia include more prolonged fever and hospitalization compared to susceptible strains. Doxycycline and respiratory fluoroquinolones are the alternatives for macrolide-resistant M. pneumoniae in adults; doxycycline is generally preferred for children over eight years. In the United States, macrolide-resistant M. pneumoniae rates remain lower than in Asia but are rising, and clinicians should consider this diagnosis in patients with atypical pneumonia not responding to macrolide therapy.15
When S. aureus or streptococci test resistant to erythromycin but susceptible to clindamycin by standard MIC testing, inducible MLSB resistance must be excluded before using clindamycin. The D-zone (double-disk diffusion) test places erythromycin and clindamycin disks 15 to 26 mm apart on an agar plate. Flattening of the clindamycin inhibition zone on the side facing the erythromycin disk (a D-shape) indicates inducible erm expression. A positive D-zone test predicts that clindamycin therapy may fail in vivo, even though the organism appears susceptible to clindamycin in isolation. Organisms with a positive D-zone test should be reported as resistant to clindamycin regardless of the MIC result.
Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34(4):482–492.
doi:10.1086/324626Schlunzen F, Zarivach R, Harms J, et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001;413(6858):814–821.
doi:10.1038/35101544Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014;143(2):225–245.
doi:10.1016/j.pharmthera.2014.03.003Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet. 1999;37(5):385–398.
doi:10.2165/00003088-199937050-00003Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990;25(Suppl A):73–82.
doi:10.1093/jac/25.suppl_a.73Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet. 1992;23(2):106–131.
doi:10.2165/00003088-199223020-00004Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41–57.
doi:10.2165/00003088-200038010-00003Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc. 1999;74(6):613–634.
doi:10.4065/74.6.613Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089–1096.
doi:10.1056/NEJMoa040582Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881–1890.
doi:10.1056/NEJMoa1003833Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.
doi:10.1086/511159Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187.
doi:10.15585/mmwr.rr7004a1Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.
doi:10.1164/rccm.200604-571STWeisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother. 1995;39(3):577–585.
doi:10.1128/AAC.39.3.577Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother. 1999;43(12):2823–2830.
doi:10.1128/AAC.43.12.2823